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Abstract: The herpes simplex virus type 1 (HSV-1) encoded E3 ubiquitin ligase, infected 
cell protein 0 (ICP0), is required for efficient lytic viral replication and regulates the switch 
between the lytic and latent states of HSV-1. As an E3 ubiquitin ligase, ICP0 directs the 
proteasomal degradation of several cellular targets, allowing the virus to counteract 
different cellular intrinsic and innate immune responses. In this review, we will focus on 
how ICP0’s E3 ubiquitin ligase activity inactivates the host intrinsic defenses, such as 
nuclear domain 10 (ND10), SUMO, and the DNA damage response to HSV-1 infection. In 
addition, we will examine ICP0’s capacity to impair the activation of interferon (innate) 
regulatory mediators that include IFI16 (IFN γ-inducible protein 16), MyD88 (myeloid 
differentiation factor 88), and Mal (MyD88 adaptor-like protein). We will also consider 
how ICP0 allows HSV-1 to evade activation of the NF-κB (nuclear factor kappa B) 
inflammatory signaling pathway. Finally, ICP0’s paradoxical relationship with USP7 
(ubiquitin specific protease 7) and its roles in intrinsic and innate immune responses to 
HSV-1 infection will be discussed. 
Keywords: herpes simplex virus; HSV; E3 ubiquitin ligase; infected cell protein 0; ICP0; 
intrinsic immunity; innate immunity 
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1. Introduction 
Ubiquitination is an important regulator of protein function and stability within cells [1,2]. This 
system is regulated by an E1-E2-E3 enzymatic cascade that catalyzes the conjugation of ubiquitin (Ub) 
to target proteins while conferring substrate specificity. Ub monomers are activated by the E1 enzyme, 
covalently linked to an E2 (of which, at least 35 E2 enzymes are present in humans [3]), and finally 
transferred from the E2 to the target protein in a mechanism facilitated by one of the many hundreds of 
E3 Ub ligases [4]. The first ubiquitination event (monoubiquitination) takes place between an internal 
lysine (K) residue within the target protein and a diglycine motif present in the C-terminus of Ub.  
As Ub itself contains 7 different lysine residues, differing polyubiquitin branch structures can form 
depending on which lysine in the initial conjugated Ub moiety is used, which itself is determined by 
the combined activities of the E2 and E3 enzymes. This conjugation of mono-, multi-, and poly-Ub 
chains can affect a target protein’s function, localization, and/or stability [5]. Typically, K48 linked Ub 
chains marks a protein for proteasomal-dependent degradation [6]. In addition, one study showed that 
ubiquitin was capable of creating linear chains of polyubiquitin through peptide bond linkage to  
N-terminal amino groups, which alter the functions of target proteins [7].  
HSV-1 (herpes simplex virus 1) is a ubiquitous human pathogen that infects about 80% of the world 
population. Infections range from vesicular eruptions around the mouth, called cold sores, to blindness 
and encephalitis [8]. A hallmark of the infection with HSV-1 is its ability to establish a lifelong latent 
or quiescent infection in the sensory neurons and to switch from latent to lytic infection when these 
neurons are stressed [8]. A lytic infection is characterized by the expression of the viral genes in a 
temporal cascade of immediate early (IE), early (E), and late (L), leading to the production of progeny 
virus. Latency, on the other hand, is characterized by the lack of infectious virions, while the viral 
genome persists as an episome in quiescently infected neurons. 
Host cells have developed multiple mechanisms to restrict viral infection. Intrinsic immunity is 
mainly composed of pre-existing proteins that are poised ready to immediately counter the early stages 
of viral infection [9,10]. This group includes members of nuclear domain 10s (ND10s), which are 
nuclear proteins important for inhibiting viral replication and repressing viral transcription [11–13].  
On the other hand, cellular innate immunity is activated by detecting viral components, which establish 
an antiviral state within the cell. Notably, the type 1 interferon (IFN) response is one of the best 
studied members of innate immunity [14]. 
Several viruses including herpesviruses have evolved varied mechanisms to disable the host cell 
antiviral responses using pathogenicity factors that are structurally and/or functionally similar to E3 
Ub ligases [15–18]. In this review we focus on the HSV-1 E3 Ub ligase, ICP0 (infected cell protein 0), 
a RING (really interesting new gene)-type E3 ligase that facilitates the transfer of Ub chains to a target 
substrate by acting as a scaffold that bridges the E2 enzyme and the target protein [19]. We will review 
ICP0’s ability to target constituents of both the intrinsic and innate branches of the immune system for 
proteasomal degradation through its E3 Ub ligase activity and the potential benefits or consequences 
for HSV-1 viral replication. It should be noted that many targets of ICP0 ubiquitination are not 
exclusively a part of intrinsic or innate defenses but are considered a component of both antiviral 
responses. For the sake of simplicity, we will primarily describe the role of these cellular factors as 
either part of intrinsic or innate immunity.  
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ICP0 is an IE protein and has been shown to play a key role in regulating the switch between the 
lytic and latent phases of the viral cycle ([20,21] and reviewed in [22]). Genetic studies using ICP0-null 
mutants showed that these viruses had impaired growth in cell culture [23], indicating that ICP0 is 
required for efficient viral replication. The requirement of ICP0 in enhancing viral replication was 
linked with its ability to transactivate all classes of HSV-1 genes (IE, E, and L) [24]. Due to the 
presence of a RING-finger motif that mediates the interaction with E2 enzymes (Figure 1), ICP0 was 
hypothesized to have E3 Ub ligase activity. This hypothesis was confirmed in a series of experiments 
that demonstrated ICP0’s ability to synthesize chains of poly-Ub in vitro and in cell culture [25–29]. 
ICP0-directed ubiquitination requires one of two known cellular E2 enzymes, UBE2D1 and  
UBE2E1 [28–31]. One report showed, using an in vitro assay, that ICP0 contained an additional E3 Ub 
ligase domain in its C-terminus, leading to the ubiquitination and degradation of the E2 protein,  
cdc34 [32]. However, a later study indicated that viral infection did not alter cdc34 protein levels [33]. 
Whether cdc34 is a bonafide ICP0 target is unclear, several publications have shown that ICP0 is 
capable of ubiquitinating a number of targets in vitro and in cell culture, including p53 [27] and the 
ubiquitin specific protease 7 (USP7) [26]. Other reports demonstrated that ICP0 mediates the 
destruction of the kinetochore proteins, which consequently blocks cell cycle progression and cellular 
proliferation [34–36]. As will be discussed below, the E3 Ub ligase activity of ICP0 plays a central role 
in HSV-1 replication by impairing components of the hosts’ intrinsic and innate antiviral responses. 
Figure 1. Functional domains and sites in ICP0 relevant to this review. The T67 
phosphorylation site, RING-finger motif, ICP0 phosphorylation (Phos) region I (amino 
acids 224–232), nuclear localization signal (NLS), USP7 binding site, ND10 localization 
domain, and SIMs (SUMO interaction motifs) 1–7, which start at amino acids 162, 174, 
331, 360, 650, 665, and 679 of ICP0, respectively [22]. 
 
2. ICP0 Counteracts the Intrinsic Antiviral Resistance of ND10s and SUMO 
ND10s are a subnuclear organelle comprised of cellular proteins that are activated by HSV-1 [37] 
and other DNA- and RNA-containing viruses [13]. ND10s appear to modulate several cellular 
biological processes, including DNA damage, apoptosis, senescence, IFN response, and protein 
degradation [13,38–40]. Several ND10 constituent proteins, including PML (promyelocytic leukemia), 
Sp100 (speckled protein of 100 kDa), hDaxx (human death domain-associated protein 6), and ATRX 
(alpha thalassemia/mental retardation syndrome X-linked) can limit the replication of an ICP0 null 
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HSV-1 mutant [41–43]. Upon viral infection, ND10-associated proteins are recruited to the incoming 
viral genome; however, ICP0’s E3 Ub ligase activity promotes the disruption of ND10 (partially 
through a C-terminal domain, Figure 1) by mediating the proteolysis (directly or indirectly) of PML 
and Sp100 [44–52] or dissociating hDaxx and ATRX [53] from ND10. The disruption of ND10s by 
ICP0 alleviates the repressive functions of ND10-associated proteins and stimulates viral transcription. 
The role of ND10s in the function of ICP0 became apparent when it was shown that depletion of PML, 
Sp100, hDaxx, or ATRX could partially complement the replication of an ICP0-null mutant but had no 
effect on wild type HSV-1 [54]. This complementation was further enhanced by the simultaneous 
depletion of two or more of these proteins [41,54]. 
ICP0 preferentially directs the degradation of PML and Sp100 that have been modified by one of 
the small ubiquitin-like modifier (SUMO) proteins [55]. In addition to affecting SUMOylated PML 
and Sp100, ICP0 reduces the overall level of SUMO-conjugated proteins in the cells, indicating that 
ICP0 acts as a SUMO targeted Ub ligase (STUbL) [55]. SUMOylation has been shown to repress 
HSV-1 replication as knock-down of the single SUMO E2 ligase, UBC9, resulted in a complete loss of 
SUMOylation in cells and enhanced the replication of an ICP0-null mutant [55]. Interestingly, ICP0 
contains several SUMO-interacting motifs (SIMs) (Figure 1), likely allowing it to bind to and regulate 
or ubiquitinate SUMO-modified proteins [55]. Overall, these results suggest that SUMO conjugation 
and/or SUMO conjugated proteins are part of the host’s intrinsic immune response. A link between 
PML, Sp100, SUMO, and innate defenses has been suggested as PML and Sp100 are IFN-stimulated 
genes (ISGs) (reviewed in [39]), with type 1 IFNs being an important part of the innate immune 
response. Furthermore, SUMOylation of PML and Sp100 increases in IFN-treated cells and correlates 
with an increase in the size and number of ND10s [56,57]. Overall, ND10s and other SUMOylated 
proteins appear to recruit cellular antiviral repressors [58], making ND10s and SUMO important 
players in the intrinsic response against HSV-1, which is ultimately incapacitated by ICP0’s E3 Ub 
ligase activity. 
Besides PML and Sp100, the ND10-associated proteins ATRX and hDaxx promote the formation 
of repressive chromatin modifications on the incoming HSV-1 genome, though the potential role of 
ICP0 in counteracting this effect is less well understood. hDaxx can largely function as a transcriptional 
repressor through the chromatinization of promoters by interacting with histone deacetylases  
(HDACs) [59,60]. As will be discussed later, ICP0 interacts with and dissociates HDACs, a 
mechanism hypothesized to be utilized by ICP0 to alleviate the hosts’ transcriptional repression on 
viral gene expression. Additionally, ATRX and hDaxx were shown to be fundamental regulators of 
replication-independent chromatin assembly by deposition at telomeres and pericentric 
heterochromatin [61–63]. A recent study using a single cell array with a CMV-promoter-regulated 
inducible transgene system showed that hDaxx and ATRX expression repressed transcriptional 
activation, and this was relieved upon expression of ICP0 [64], supporting a role of these factors in 
silencing viral genomes by an intrinsic antiviral mechanism. 
3. ICP0 Interferes With the DNA Damage Response, an Intrinsic Defense Against HSV-1 
During DNA damage, several signal transduction pathways are initiated with the goal of protecting 
cells from accumulating or propagating genetic abnormalities. The main signaling pathway mediators 
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that initiate DNA damage response (DDR) include members of the phosphoinositide 3-kinase related 
kinases (PIKKs): DNA-dependent protein kinase (DNA-PK), ataxia telangectasia mutated (ATM) 
kinase, and ATM and Rad3 related (ATR) kinase. In addition, the poly (ADP- ribose) polymerase 
(PARP) family contributes to this signaling. DNA damage by double strand break (DSBs) result in the 
activation of DNA-PK, ATM, and PARP1/2 [65]; on the other hand, single stranded breaks (SSBs) 
activate ATR or PARP. Repair of the damaged DNA occurs by homologous recombination or  
non-homologous end joining repair, and in certain instances, apoptosis can be induced if the damage is 
extensive [66–68]. Typically, signaling through ATR and ATM promotes apoptosis, while DNA-PK 
leads to non-homologous end-joining repair [69]. 
Several DNA viruses manipulate the DDR, activating or repressing it to facilitate viral replication 
(reviewed in [69]). HSV-1 infection has been shown to activate the ATM pathway by inducing the 
phosphorylation of ATM and its downstream targets [70–72]. Additionally, it has been recently 
reported that HSV-1 infection is associated with activation of PARP1/2. ICP0 has been shown to 
activate the cellular kinase checkpoint kinase 2 (Chk2), an ATM downstream substrate, blocking the 
cell cycle in the G2/M phase, an activity which enhances viral replication [73]. On the other hand, 
DDR activated by HSV-1 is counteracted through the E3 Ub ligase activity of ICP0. Specifically, ICP0 
has been shown to direct the proteasomal dependent degradation of the catalytic subunit of DNA-PK 
(DNA-PKcs) [74,75], which interrupts its repair function and enhances viral replication. Interestingly 
DNA-PK has been recently shown to activate innate immune mechanisms in response to DNA  
viruses [76], and this adds potentially another mechanism by which ICP0 counteracts innate immunity.  
In addition to DNA-PKcs, ICP0 was shown to ubiquitinate and direct the degradation of RNF8 and 
RNF168 [77,78]. RNF8 and RNF168 are E3 Ub ligases that act as key mediators of the ATM pathway 
by poly-ubiquitinating histones, a signal that acts to recruit downstream effectors such as p53BP and 
BRCA1 to sites of DSBs [79]. Interestingly, extrinsic expression of RNF8 repressed viral  
transcription [77], and RNF8 degradation is regulated by single site phosphorylation (T67) on ICP0 [80], 
which facilitates its binding to ICP0. Regarding PARP signaling, ICP0 mediates the proteolysis of poly 
(ADP-ribose) glycohydrolase (PARG), an enzyme that removes PAR (poly (ADP- ribose)) chains on 
cellular proteins conjugated by PARP. ICP0 modulation of PARG has been proposed to facilitate viral 
infection by promoting the PARylation of target proteins, including PARP, involved in the DDR [81]. 
Overall, ICP0 inhibition of different DNA damage proteins via its E3 Ub ligase enhances viral 
transcription and replication. 
4. ICP0’s E3 Ub Ligase Activity Modulates the Activation and Establishment of the IFN 
Response, an Innate Host Defense 
A link between HSV-1 ICP0, and the IFN response was initially established when it was shown that 
ICP0 mutant viruses replicated poorly in the presence of type I IFNs compared to wild type HSV-1 [82]. 
In fact, ICP0 was shown to inhibit the induction of IFN-stimulated genes (ISGs) during viral infection [83]. 
Overall, the expression of ISGs results in the establishment of an antiviral state in cells due to the 
contribution of the individual activities of many of these interferon stimulated proteins. In fact, ICP0 is 
known to impair the activation of the type I IFN response through regulatory factors by affecting the 
levels or activity of many of these proteins amongst which are IFI16, MYD88, and Mal.  
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4.1. IFI16 
IFI16, or IFN γ-inducible protein 16, is a DNA sensor that initiates a signaling pathway to induce 
the expression of type I IFNs. IFI16 was shown to induce IFN-β in response to HSV-1 [84,85] and 
IFI16’s activation was reportedly linked to its subcellular localization that is strongly linked to its 
acetylation modification status [86]. The activation of IFI16 upon HSV-1 infection could be 
counteracted by the expression of ICP0, which promotes its degradation. Further support for a role of 
IFI16 in counteracting viral replication came from an experiment showing that the depletion of IFI16 
partially enhanced the replication of an ICP0-null mutant [84,87]. Interestingly, in addition to its role 
inducing the IFN response, IFI16 was proposed to silence the HSV-1 genome by triggering 
heterochromatin association with viral DNA, giving IFI16 an additional function as part of the intrinsic 
antiviral response. IFI16 promotes the deposition of repressive histone H3K9 trimethylation 
modifications on HSV chromatin while reducing histone H3K4 trimethylation, which recruits enzymes 
that add heterochromatin marks for silencing exogenous DNA [88]. This highlights a role of IFI16 in 
the intrinsic immunity to HSV-1. A recent report, however, has challenged the role of IFI16 in the 
biology of HSV-1, as the authors of the study presented data reporting that IFI16 degradation was not 
dependent on ICP0 [87]. Potential explanations regarding the different outcomes between the former 
and latter studies are that different cell types and conditions were utilized. As examples, the stability of 
IFI16 may vary in different cell lines, a range of multiplicities of infection were used, and various 
concentrations of the proteasome inhibitor, MG132, tested could have indirect effects on  
HSV-1 replication [89]. 
4.2. MyD88 and Mal 
Toll like receptors (TLRs) are instrumental in the initial sensing of pathogens and activation of 
signaling pathways that will ultimately activate the type 1 IFN response [90]. ICP0 was shown to 
reduce the inflammatory response that TLR2 triggers upon HSV-1 infection [91]. MyD88 (myeloid 
differentiation factor 88) is an essential adaptor molecule that promotes inflammatory cytokines upon 
activation of all TLRs. This pathway’s cascade activates the transcription factors NF-κB (nuclear 
factor kappa B) or AP-1 (activator protein 1) upon initial interaction of MyD88 with the TLRs. 
Another adaptor molecule necessary in the MyD88-dependent activation of TLR2 and TLR4 is the 
protein known as Toll/interleukin-1 receptor domain-containing adapter protein (TIRAP) or MyD88 
adaptor-like protein (Mal) [92]. ICP0, independent of other viral factors, can block signaling 
downstream of MyD88 and diminish MyD88 and Mal protein levels [92]. In the latter case, the 
reduction in MyD88 and Mal protein levels is dependent on the function of ICP0’s E3 Ub ligase 
activity and the cellular proteasome [91]. These data indicate that ICP0 promotes the degradation of 
specific TLR adaptor molecules to inhibit the innate inflammatory responses to HSV-1 infection. 
4.3. NF-κB Signaling 
Ubiquitination is essential in the regulation of the tumor necrosis factor (TNF)-α-mediated NF-κB 
signal transduction pathway [93]. TNF-α is a pro-inflammatory cytokine that is activated upon HSV-1 
infection and leads to the induction and regulation of innate and adaptive immune responses through 
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the NF-κB pathway. NF-κB is a family of proteins in which the heterodimer, p65 and p50, represents 
the predominant form of the transcription factor complex (reviewed in [94]). Several HSV-1 proteins 
have been shown to perturb NF-κB signaling [95–99]. ICP0 in particular can interact with the NF-κB 
family members, p65 and p50, and promote the proteasomal degradation of p50; p50 degradation 
prevents the nuclear translocation of p65, ultimately impeding NF-κB dependent gene expression [100]. 
In contrast to its NF-κB signaling inhibitory activities, ICP0 has been reported to also ubiquitinate 
IκBα, consequently stimulating the transcription of NF-κB target genes [101]. Furthermore, NF-κB 
stimulation can directly benefit HSV-1 replication as it was shown that NF-κB can be recruited to the 
ICP0 promoter, activating ICP0 transcription and replication [89]. A potential explanation for ICP0’s 
ability to impair and activate NF-κB signaling is that other HSV-1 proteins might interfere with the 
antiviral function of specific NF-κB-stimulated proteins; these perturbations are ultimately beneficial 
for viral replication. 
5. ICP0 Directs the Degradation of USP7, a Mediator of Intrinsic and Innate Immunity 
The ubiquitin specific protease 7 (USP7), also known as herpes-associated ubiquitin specific 
protease (HAUSP), is a cellular protein that was initially found to strongly interact with the C-terminus 
of ICP0 [102,103]. USP7 partially colocalizes with ND10, a phenotype that is enhanced in the 
presence of ICP0 (Figure 1) [104]. Interrupting the interaction between ICP0 and USP7 reduces 
ICP0’s transactivation activity and viral plaque formation without affecting ND10 disruption [105]. 
Interestingly, this interaction has been shown to stabilize ICP0 protein levels early during viral 
infection [106]; however, later during the viral life cycle, ICP0 directs the degradation of USP7, a 
function that requires ICP0’s RING-finger domain [26] and is regulated by ICP0 phosphorylation [107]. 
In addition to affecting its stability, ICP0 has been shown to recruit USP7 to the cytoplasm [108]. 
Cytoplasmic USP7 has been reported to interfere with TLR signaling by the de-ubiquitination of 
TRAF6 and IKKγ, leading to an inhibition of NF-κB [108]. Another facet of USP7 regulation is that it 
can interact with and regulate the levels of the E2 enzyme, UbcH6, attenuating its enzymatic  
functions [109]. Given that UbcH6 interacts with ICP0 to promote the ubiquitination of ICP0 targets 
PML, p53, and USP7 [26,27,110], it is possible that USP7’s interaction with UbcH6 may modulate 
ICP0’s E3 Ub ligase activity. 
USP7 has been described to have a role in transcriptional repression by stabilizing subunits of the 
polycomb repressive complex (PRC) [111] and the repressor element 1-silencing transcription factor 
(REST) [112]. Notably, components of two PRCs have been found to associate with latent HSV-1 
genomes [113,114], and ICP0 facilitates HSV-1 reactivation from quiescent infection, which requires 
its RING-finger motif [115,116]. During reactivation, ICP0 appears to decrease the amount of histones 
associated with the viral genome while increasing histone acetylation, a modification that typically 
stimulates transcription [117,118]. These alterations in the chromatinization of the HSV genome 
during lytic infection and reactivation may also be tied to ICP0’s interactions with and relocalization 
of histone deacetylases (HDACs), whose activities repress transcription [119]. Interestingly, an ICP0 
mutant altered at a series of phosphorylation sites adjacent to the RING-finger (Figure 1), which does 
not efficiently induce the degradation of USP7 during lytic infection, is impaired for lytic infection and 
viral reactivation but not latency [107,120]. These results suggests that reductions in USP7 levels 
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mediated by ICP0 may alter chromatinization of the viral genome by destabilizing PRC and REST 
levels to promote gene expression and reactivation, which is regulated by ICP0 phosphorylation. 
An additional aspect of the ICP0/USP7 interaction puzzle is the effect of USP7 degradation on p53 
protein levels. p53 has been shown to be a target of ICP0 ubiquitination in vitro [27]; however, the 
levels of p53 are actually stabilized in response to HSV-1 infection. Although the increase in p53 
stability can be attributed to USP7 degradation by ICP0, an event which will result in decreased 
stability of MDM2, an E3 Ub ligase that directs p53 for degradation [121], p53 stabilization in 
response to HSV-1 infection has been shown to be independent of ICP0 or USP7 [122]. As different 
stress conditions such as IFN-signaling can result in other post-translational modifications of p53, 
inducing acetylation, phosphorylation, and SUMOylation, these modifications are critical for p53’s 
ability to induce apoptosis upon viral infection or senescence in response to IFN treatment [123]. Thus, 
it is possible that the functional relevance of p53 ubiquitination by ICP0 may be evident only under 
these circumstances. Indeed ICP0 was shown to inhibit apoptosis when the osteosarcoma cell line, 
U2OS cells, were exposed to UV irradiation [27]. More studies are required to address the significance 
of p53 ubiquitination by ICP0 in acute viral infection and reactivation from latency and the effect of 
USP7 degradation on this process. 
6. Conclusions 
In order to survive within their host, most viruses have developed several mechanisms to counteract 
host defenses. The E3 Ub ligase activity of ICP0 is key for HSV-1 evasion of both intrinsic and innate 
immune responses (Figure 2). This activity of ICP0 is required for efficient viral gene expression and 
acute viral replication. ICP0 causes the disruption of ND10s, counteracts the DNA damage response, 
inhibits the IFN pathway, and interferes with cellular transcription repression pathways. Notably, 
different members of the intrinsic immune response are also considered part of the innate pathway 
(Figure 2). Interestingly, ICP0 uses different mechanisms to target proteins for degradation or 
dissociation. For example, the DNA damage protein RNF8 was shown to bind to ICP0 in a 
phosphorylation dependent manner. On the other hand, several ND10 components including select 
PML isoforms, Sp100, and hDaxx have not been shown to directly interact with ICP0. This 
observation indicates that ICP0 can promote the degradation of its targets either directly or indirectly 
and puts forward the tangible possibility that novel ICP0-cellular binding partners and targets of its 
degradation will be discovered. Elucidating new targets of ICP0 degradation will help us understand 
the mechanisms by which ICP0 targets different and interrelated antiviral pathways (e.g., Mal in the 
IFN response and NF-κB signaling). 
In sum, ICP0, through its E3 ubiquitin ligase activity, modulates an array of different and 
overlapping cellular pathways to ultimately inactivate the cell’s intrinsic and innate antiviral responses, 
allowing HSV-1 to replicate and persist in its host. 
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Figure 2. The HSV-1 ICP0 E3 ubiquitin ligase activity counteracts components of host 
intrinsic and innate immunity by targeting the degradation or dissociation of specific 
cellular proteins. Many ICP0 targets are multi-functional and participate in both intrinsic 
and innate antiviral responses and affect several processes, which includes (1) Viral 
transcription: PML, Sp100, and SUMO; (2) Viral genome silencing: IFI16; (3) Inflammatory 
mechanisms and NF-κB regulation: IFI16, MyD88, Mal, NF-κB, and IκB; (4) Viral 
replication: PARG; (5) DNA damage response: RNF168, RNF8, and DNA-PKcs; and  
(6) ICP0 destabilization, TLR signaling, Chromatinization, NF-κB signaling: USP7. 
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